A Randomized, Double-blinded, Placebo-controlled, Single Center, Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Emapalumab After a Single Intravenous Dose in Japanese Healthy Volunteers.
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Emapalumab (Primary)
- Indications COVID 2019 infections; Haemophagocytic lymphohistiocytosis; Transplant rejection
- Focus Pharmacokinetics
- Sponsors Swedish Orphan Biovitrum
- 09 Aug 2021 Status changed from recruiting to completed.
- 09 Jun 2021 Planned primary completion date changed from 1 May 2021 to 1 Jun 2021.
- 23 Feb 2021 New trial record